A Citigroup analyst initiated coverage on Acadia with a Buy rating and announced a price target of $38. Additionally the US District Court for the District of Delaware has issued a summary judgment in favor of Acadia, affirming the validity of the NUPLAZID (pimavanserin) '740 composition of matter patent on all grounds
A Citigroup analyst initiated coverage on Acadia with a Buy...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.29 |
Change
1.020(8.31%) |
Mkt cap ! $1.666B | |||
| Open | High | Low | Value | Volume |
| $12.95 | $13.32 | $12.79 | $5.888M | 452.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 360 | $13.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.30 | 2632 | 3 |
View Market Depth
| Last trade - 13.28pm 06/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |